| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/14/2002 | WO2002011740A2 'slow release' pharmaceutical compositions comprising lithium carbonate |
| 02/14/2002 | WO2002011739A1 Methods for preventing pressure induced apoptotic neural cell death |
| 02/14/2002 | WO2002011733A1 Pharmaceutical composition comprising condensed indole compound |
| 02/14/2002 | WO2002011731A2 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches |
| 02/14/2002 | WO2002011727A1 Stable pergolide mesylate and process for making same |
| 02/14/2002 | WO2002011724A2 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2002011714A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | WO2002011713A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 02/14/2002 | WO2002011712A2 Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| 02/14/2002 | WO2002011708A2 Methods for inducing apolipoprotein e secretion |
| 02/14/2002 | WO2002011703A1 Hybrid neuroprosthesis for the treatment of brain disorders |
| 02/14/2002 | WO2002011666A2 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 02/14/2002 | WO2002011513A1 A novel polypeptide-human ehd protein 9.57 and the polynucleotide encoding said polypeptide |
| 02/14/2002 | WO2001098471A8 Human phosphodiesterases |
| 02/14/2002 | WO2001072838A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/14/2002 | WO2001072328A3 Methods of treating diseases with activated protein c |
| 02/14/2002 | WO2001070766A3 Therapeutic anti-cytomegalovirus compounds |
| 02/14/2002 | WO2001068603A3 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001059120A3 Il-17 like molecules and uses thereof |
| 02/14/2002 | WO2001058951A3 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 02/14/2002 | WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 02/14/2002 | WO2001058462A3 Models, methods and materials relating to clinical conditions associated with reactive oxygen species |
| 02/14/2002 | WO2001056598A3 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 02/14/2002 | WO2001055119A3 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041807A3 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 02/14/2002 | WO2001041750A3 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 02/14/2002 | WO2001029055A3 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 02/14/2002 | WO2001014418A3 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 02/14/2002 | WO2000073337A9 Polymer conjugates of hedgehog proteins and uses |
| 02/14/2002 | WO2000061188A9 Sodium channel blocker compositions and the use thereof |
| 02/14/2002 | US20020019992 Transgenic non-human mammals with progressive neurologic disease |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019540 Conformationally constrained compounds as pharmaceutical agents |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |
| 02/14/2002 | US20020019528 Process for the preparation of 2-phenyl-imidazo [1, 2-a] pyridine-3-acetamides |
| 02/14/2002 | US20020019526 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/14/2002 | US20020019525 Pyrido [2,3-b] indolizine derivatives and aza analogues thereof; CRF1 specific ligands |
| 02/14/2002 | US20020019524 Chemical synthesis of morpholine derivatives |
| 02/14/2002 | US20020019519 KIAA0551 polynucleotides and polypeptides use |
| 02/14/2002 | US20020019515 Novel spoIIIE |
| 02/14/2002 | US20020019426 Therapy for amyotropic lateral sclerosis |
| 02/14/2002 | US20020019425 Anticancer agents; administering p53 gene or protein |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019410 Central nervous system disorders |
| 02/14/2002 | US20020019406 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands |
| 02/14/2002 | US20020019403 Inhibit amyloid protein deposits |
| 02/14/2002 | US20020019401 Psychological disorders; adjustment of dopamine concentration |
| 02/14/2002 | US20020019398 Methods of making and using N-desmethylzopiclone |
| 02/14/2002 | US20020019396 Pharmaceutically active morpholinol |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019392 By administering indole compounds such as 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5 -ol; epilepsy, asthma, eating disorders, obesity, neurodegenertive conditions, schizophrenia |
| 02/14/2002 | US20020019388 (cis)-6-(3-pyridinyl)-3,6-diazabicyclo(3.2.0) heptane for example; Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder, depression, nicotinic withdrawal syndrome, Tourette's syndrome, and schizophrenia |
| 02/14/2002 | US20020019383 3-amido or 3-sulfonylamino azetidine compounds and their preparation; high affinity for cannabinoid receptor CB1 type, useful in treating central nervous system, immune, gastrointestinal or cardiovascular disorders, drug abuse |
| 02/14/2002 | US20020019380 1-(6-((dimethylamino)methyl)-1-methyl-2,3,5,6-tetrahydro-1H -cyclobuta(f)indol-6-yl)cyclohexanol, for example; treating psychological disorders such as depression, panic attacks, phobias, drug abuse, as well as obesity and bulemia |
| 02/14/2002 | US20020019360 Treatment for cardiovascular disease |
| 02/14/2002 | US20020019340 Polymer stabilized neuropeptides |
| 02/14/2002 | US20020019335 Methods of investigating, diagnosing, and treating amyloidosis |
| 02/14/2002 | US20020019016 Classifying nervous system disorders; obtain tissue, detect preferential tau protein in sample |
| 02/14/2002 | US20020018995 Detecting brain disorders; obtain sample tissue, monitor tau mutant isoform duplications in cell, compare to wild type, amplification in tau mutant isoforms indicates brain disorders |
| 02/14/2002 | US20020018810 Controlled release oxycodone compositions |
| 02/14/2002 | US20020018809 Analgesics; rheumatic diseases; muscular disorders; sleep disorders |
| 02/14/2002 | US20020018787 Synergistic mixture of dimethylglycine and mussel extract |
| 02/14/2002 | CA2504880A1 Polymorphs of zaleplon and methods for the preparation thereof |
| 02/14/2002 | CA2438446A1 Methods for the preparation of mirtazapine intermediates |
| 02/14/2002 | CA2423519A1 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | CA2420967A1 Heterocyclic compounds as ligands of the gabaa receptor |
| 02/14/2002 | CA2419132A1 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway |
| 02/14/2002 | CA2419036A1 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 02/14/2002 | CA2419030A1 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| 02/14/2002 | CA2419027A1 Bicyclic compounds as h3 receptor ligands |
| 02/14/2002 | CA2418995A1 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/14/2002 | CA2418951A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | CA2418946A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 02/14/2002 | CA2418915A1 Stable pergolide mesylate and process for making same |
| 02/14/2002 | CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | CA2418895A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | CA2418832A1 Quinolene derivatives as anti-inflammation agents |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418369A1 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 02/14/2002 | CA2418144A1 Urocortin proteins and uses thereof |
| 02/14/2002 | CA2417967A1 Azabicyclic derivatives and their therapeutic use |
| 02/14/2002 | CA2417930A1 Pharmaceutical compositions containing lithium carbonate |
| 02/14/2002 | CA2417828A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | CA2417676A1 Sequences for integrin alpha-8 |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | CA2415467A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/13/2002 | EP1179350A2 Encapsulated cell system for implantation into the human CNS |
| 02/13/2002 | EP1179348A2 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179063A2 Genes expressed in hippocampus |